Academic Journals Database
Disseminating quality controlled scientific knowledge

Management of patients with advanced non-small cell lung cancer: role of gefitinib

ADD TO MY LIST
 
Author(s): Vamsidhar Velcheti | Daniel Morgensztern | Ramaswamy Govindan

Journal: Biologics : Targets & Therapy
ISSN 1177-5475

Volume: 2010;
Issue: default;
Start page: 83;
Date: 2010;
Original page

ABSTRACT
Vamsidhar Velcheti1, Daniel Morgensztern2,3,4, Ramaswamy Govindan3,41Department of Internal Medicine, Ochsner Clinic Foundation, New Orleans, LA, USA; 2Division of Hematology-Oncology, St. Louis Veterans Hospital, St. Louis, MO, USA; 3Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA; 4Alvin J Siteman Cancer Center, St. Louis, MO, USAAbstract: Gefitinib is the first epidermal growth factor receptor tyrosine-kinase inhibitor approved for the treatment of advanced non-small cell lung cancer (NSCLC). Its failure to improve survival in a placebo-control study, however, led to its withdrawal in the United States though it is available in many other countries Subsequent studies nevertheless showed comparable efficacy for gefitinib and docetaxel in the second-line therapy. Gefitinib significantly improved progression-free survival compared to chemotherapy in patients with activating mutations in the epidermal growth factor receptor tyrosine kinase mutations. This review will discuss the results of these large randomized studies and discuss the role of gefitinib in the treatment of advanced NSCLC.Keywords: gefitinib, non-small cell lung cancer
Affiliate Program      Why do you need a reservation system?